Lopinavir/r versus nelfinavir as salvage therapy

被引：1
|
作者：
Resino, S [1 ]
Alvaro-Meca, A
de José, MI
Gurbindo, MD
Ramos, JT
Martin-Fontelos, P
Muñoz-Fernández, MA
机构：
[1] Hosp Gregorio Maranon, Lab Immuno Biol Mol, Madrid, Spain
[2] Hosp La Paz, Serv Pediat, La Paz, Bolivia
[3] Hosp Gregorio Maranon, Serv Inmuno Pediat, Madrid, Spain
[4] Hosp Carlos III, Serv Pediat Infecc, Madrid, Spain
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2005年 / 24卷 / 04期
关键词：
D O I：
10.1097/01.inf.0000157922.19139.90
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：392 / 393
页数：2
相关论文
共 50 条
  • [31] Lopinavirus non-lopinavir containing salvage therapy for patients failing at least one HAART regimen
    Foster, JA
    Canter, SC
    Chen, JS
    Conway, DH
    PEDIATRIC RESEARCH, 2003, 53 (04) : 333A - 333A
  • [32] Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy
    Loutfy, M
    Raboud, J
    Thompson, C
    Tseng, A
    Abdurrahman, Z
    Kovacs, C
    Rachlis, A
    Phillips, E
    Rubin, G
    Gough, K
    Walmsley, S
    HIV CLINICAL TRIALS, 2003, 4 (05): : 301 - 310
  • [33] Risk factors for body fat composition changes in patients treated with lopinavir/ritonavir or nelfinavir
    da Silva, B
    King, M
    Cernohous, P
    Kelly, C
    Tressler, R
    Brun, S
    ANTIVIRAL THERAPY, 2003, 8 (04) : L68 - L68
  • [34] Lopinavir/r plus Efavirenz combination as a potent NRTI sparing antiretroviral therapy
    Henrivaux, Philippe
    Fairon, Yvette
    Kabamba, Benoit
    Yombi, Jean-Cyr
    Goubau, Patrick
    Vandercam, Bernard
    RETROVIROLOGY, 2010, 7 : 31 - 32
  • [35] Analysis of the emergence of secondary mutations with or without primary protease inhibitor resistance in antiretroviral therapy-naive subjects with detectable viral load on nelfinavir or lopinavir/ritonavir therapy
    Kempf, D
    King, M
    Bauer, E
    Moseley, J
    Bernstein, B
    Sun, E
    ANTIVIRAL THERAPY, 2002, 7 : S157 - S157
  • [36] Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir
    Guest, JL
    Ruffin, C
    Tschampa, JM
    DeSilva, KE
    Rimland, D
    PHARMACOTHERAPY, 2004, 24 (06): : 727 - 735
  • [37] R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma.
    Freyer, Craig
    George, Timothy
    Price, Samantha
    Shah, Bijal Dinesh
    Bello, Celeste M.
    Sokol, Lubomir
    Sotomayor, Eduardo M.
    Cultrera, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Lopinavir-Ritonavir Monotherapy Versus Lopinavir-Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week Analysis
    Arribas, Jose R.
    Delgado, Rafael
    Arranz, Alberto
    Munoz, Rosa
    Portilla, Joaquin
    Pasquau, Juan
    Perez-Elias, Maria J.
    Iribarren, Jose A.
    Rubio, Rafael
    Ocampo, Antonio
    Sanchez-Conde, Matilde
    Knobel, Hernando
    Arazo, Piedad
    Sanz, Jesus
    Lopez-Aldeguer, Jose
    Montes, Maria L.
    Pulido, Federico
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (02) : 147 - 152
  • [39] Virological success of lopinavir/ritonavir salvage regimen is affected by an lopinavir/ritonavir-related increasing number of mutations
    Bongiovanni, M
    Bini, T
    Adorni, F
    Meraviglia, P
    Capetti, A
    Tordato, F
    Cicconi, P
    Chiesa, E
    Cordier, L
    Cargnel, A
    Landonio, S
    Rusconi, S
    Monforte, AD
    ANTIVIRAL THERAPY, 2003, 8 (03) : 209 - 214
  • [40] Cost of therapy for ARV naive HIV-infected patients: Fosamprenavir/ritonavir versus nelfinavir
    Lee, WC
    Hoffmann, M
    Stephens, J
    Williams, K
    Liu, LZ
    Pashos, CL
    VALUE IN HEALTH, 2005, 8 (03) : 313 - 313
12345